Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Brain metastases and prognosis

Johung – JCO 2016 * Pacheco – JTO 2019

63.3 months (>5 years)

49.5 months

(> 4years)

Retrospective. N=90. Majority RT

N=48

N=45

N=17

mOS with crizotinib upfront:

86 mo. (6.8 y)

Retrospective. N=110. 30% BM at baseline

(59% evaluable, 85% local treatment)

BM not bad prognosis. The issue is receiving an ALK TKI, but does really matter which one?